Background and aims: In the ADHERE trial (NCT04281472), subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20), a neonatal Fc inhibitor, reduced relapse risk and improved disability scores in chronic inflammatory demyelinating polyneuropathy (CIDP). This evidence concerns the gene SPAM1 and chronic inflammatory demyelinating polyradiculoneuropathy.